VANCOUVER, British Columbia, April 22, 2005 (PRIMEZONE) -- Ongoing third party evaluations of ProtoKinetix, Inc.'s (OTCBB:PKTX) proprietary synthesized Antifreeze Glycoproteins (AFGP's) continue to confirm the maintenance of cell integrity and survivability in the presence of AFGP at all temperatures ranging from 22 degrees Celsius to zero degrees Celsius. Currently, blood platelets are stored at room temperature and due to bacterial contamination at these temperatures, they must be discarded after five days. The ability to extend the shelf life of platelets will have a dramatic impact on the world's blood supply.
Imad Nasrallah, president of ProteoCell Biotechnologies, Inc. states "We have observed that in the presence of AFGP, the survivability of blood platelets is significantly higher and more stable from room temperatures down to zero degrees Celsius. This difference becomes more pronounced as the temperature declines toward zero." Testing continues with the preservation of various cells, tissues and organs.
The Company states that it has entered into discussions with several major corporations and government institutions regarding the commercial application of the AFGP product lines.
About ProtoKinetix:
ProtoKinetix, Inc. is a scientific development company whose mission is the advancement of human health care. The Company's first entry into the commercial marketplace will be the launch of the first synthetically replicated antifreeze glycoprotein (AFGP). PKTX has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This integrated scientific approach combines the disciplines of physics, chemistry and molecular biology in order to fast-track product development.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors,
Dr. John Todd, President